Literature DB >> 12211409

Roflumilast Altana Pharma.

Peter Reid1.   

Abstract

Roflumilast is a specific PDE4 inhibitor being developed by Altana Pharma (formerly known as Byk Gulden) for the potential treatment of asthma and chronic obstructive pulmonary disease [312928].

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12211409

Source DB:  PubMed          Journal:  Curr Opin Investig Drugs        ISSN： 1472-4472


  8 in total

1.  Effects of piclamilast, a selective phosphodiesterase-4 inhibitor, on oxidative burst of sputum cells from mild asthmatics and stable COPD patients.

Authors:  Kai M Beeh; Jutta Beier; Claudia Lerch; Ann K Schulz; Roland Buhl
Journal:  Lung       Date:  2004       Impact factor: 2.584

2.  Lack of a pharmacokinetic interaction between steady-state roflumilast and single-dose midazolam in healthy subjects.

Authors:  Nassr Nassr; Gezim Lahu; Oliver von Richter; Felix Reutter; Dietrich Knoerzer; Karl Zech; Katharina A Erb; Barbara Schug; Henning Blume; Robert Hermann
Journal:  Br J Clin Pharmacol       Date:  2006-09-29       Impact factor: 4.335

3.  Effects of rifampicin on the pharmacokinetics of roflumilast and roflumilast N-oxide in healthy subjects.

Authors:  Nassr Nassr; Andreas Huennemeyer; Rolf Herzog; Oliver von Richter; Robert Hermann; Manuela Koch; Kevin Duffy; Karl Zech; Gezim Lahu
Journal:  Br J Clin Pharmacol       Date:  2009-10       Impact factor: 4.335

4.  Steady-state pharmacokinetics of roflumilast and roflumilast N-oxide in patients with mild and moderate liver cirrhosis.

Authors:  Robert Hermann; Nassr Nassr; Gezim Lahu; Eva Péterfai; Dietrich Knoerzer; Rolf Herzog; Karl Zech; Christian de Mey
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

5.  Interactions between cGMP- and cAMP-pathways are involved in the regulation of penile smooth muscle tone.

Authors:  Stefan Uckert; Petter Hedlund; Eginhard Waldkirch; Michael Sohn; Udo Jonas; Karl-Erik Andersson; Christian G Stief
Journal:  World J Urol       Date:  2004-03-26       Impact factor: 4.226

6.  Design of phosphodiesterase 4D (PDE4D) allosteric modulators for enhancing cognition with improved safety.

Authors:  Alex B Burgin; Olafur T Magnusson; Jasbir Singh; Pam Witte; Bart L Staker; Jon M Bjornsson; Margret Thorsteinsdottir; Sigrun Hrafnsdottir; Timothy Hagen; Alex S Kiselyov; Lance J Stewart; Mark E Gurney
Journal:  Nat Biotechnol       Date:  2009-12-27       Impact factor: 54.908

Review 7.  Biological targets for therapeutic interventions in COPD: clinical potential.

Authors:  Girolamo Pelaia; Alessandro Vatrella; Luca Gallelli; Teresa Renda; Mario Caputi; Rosario Maselli; Serafino A Marsico
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2006

Review 8.  Treating COPD with PDE 4 inhibitors.

Authors:  William M Brown
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2007
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.